Loading
A second PD-1 antibody, camrelizumab, also lengthened progression-free survival when added to gemcitabine and cisplatin in metastatic nasopharyngeal cancer, confirming that chemo-immunotherapy is the new first-line standard.
Chinese multicentre randomised double-blind phase 3 trial of 263 patients with recurrent or metastatic nasopharyngeal carcinoma assigned to camrelizumab or placebo with gemcitabine and cisplatin, followed by maintenance.
Median progression-free survival was 9.7 months with camrelizumab against 6.9 months with placebo (hazard ratio 0.54), with a higher response rate; reactive cutaneous capillary endothelial proliferation, characteristic of camrelizumab, was common but mostly mild.
Together with JUPITER-02 and RATIONALE-309, this trial made PD-1 blockade plus gemcitabine-cisplatin the first-line standard for metastatic nasopharyngeal carcinoma.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Gemcitabine + cisplatin.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Gemcitabine + cisplatin.
Shares CAPTAIN-1st, Recurrent and metastatic nasopharyngeal carcinoma.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Camrelizumab, Gemcitabine + cisplatin.